Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
HealthEast Cancer Care at St. Joseph's Hospital
mi
from
St Paul, MN
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
HealthEast Cancer Care at St. Joseph's Hospital
mi
from
St Paul, MN
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Park Nicollet Cancer Center
mi
from
St. Louis Park, MN
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Park Nicollet Cancer Center
mi
from
St. Louis Park, MN
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Regions Hospital Cancer Care Center
mi
from
St. Paul, MN
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Regions Hospital Cancer Care Center
mi
from
St. Paul, MN
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
United Hospital
mi
from
St. Paul, MN
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
United Hospital
mi
from
St. Paul, MN
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Ridgeview Medical Center
mi
from
Waconia, MN
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Ridgeview Medical Center
mi
from
Waconia, MN
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
HealthEast Cancer Care at Woodwinds Health Campus
mi
from
Woodbury, MN
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
HealthEast Cancer Care at Woodwinds Health Campus
mi
from
Woodbury, MN
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Minnesota Oncology and Hematology PA-Woodbury
mi
from
Woodbury, MN
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Minnesota Oncology and Hematology PA-Woodbury
mi
from
Woodbury, MN
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
CCOP - MeritCare Hospital
mi
from
Fargo, ND
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
CCOP - MeritCare Hospital
mi
from
Fargo, ND
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Sanford Broadway Clinic
mi
from
Fargo, ND
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Sanford Broadway Clinic
mi
from
Fargo, ND
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Wood County Oncology Center
mi
from
Bowling Green, OH
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Wood County Oncology Center
mi
from
Bowling Green, OH
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Grandview Hospital
mi
from
Dayton, OH
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Grandview Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Good Samaritan Hospital
mi
from
Dayton, OH
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Good Samaritan Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Samaritan North Cancer Care Center
mi
from
Dayton, OH
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Samaritan North Cancer Care Center
mi
from
Dayton, OH
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Veterans Affairs Medical Center - Dayton
mi
from
Dayton, OH
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Veterans Affairs Medical Center - Dayton
mi
from
Dayton, OH
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
CCOP - Dayton
mi
from
Dayton, OH
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
CCOP - Dayton
mi
from
Dayton, OH
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Blanchard Valley Medical Associates
mi
from
Findlay, OH
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Blanchard Valley Medical Associates
mi
from
Findlay, OH
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Fremont Memorial Hospital
mi
from
Fremont, OH
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Fremont Memorial Hospital
mi
from
Fremont, OH
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Kenton Oncology, Incorporated
mi
from
Kenton, OH
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Kenton Oncology, Incorporated
mi
from
Kenton, OH
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Charles F. Kettering Memorial Hospital
mi
from
Kettering, OH
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Charles F. Kettering Memorial Hospital
mi
from
Kettering, OH
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Lima Memorial Hospital
mi
from
Lima, OH
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Lima Memorial Hospital
mi
from
Lima, OH
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Northwest Ohio Oncology Center
mi
from
Maumee, OH
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Northwest Ohio Oncology Center
mi
from
Maumee, OH
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
St. Luke's Hospital
mi
from
Maumee, OH
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
St. Luke's Hospital
mi
from
Maumee, OH
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Middletown Regional Hospital
mi
from
Middletown, OH
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Middletown Regional Hospital
mi
from
Middletown, OH
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
St. Charles Mercy Hospital
mi
from
Oregon, OH
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
St. Charles Mercy Hospital
mi
from
Oregon, OH
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Toledo Clinic - Oregon
mi
from
Oregon, OH
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Toledo Clinic - Oregon
mi
from
Oregon, OH
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Firelands Regional Medical Center
mi
from
Sandusky, OH
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Firelands Regional Medical Center
mi
from
Sandusky, OH
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
North Coast Cancer Care, Incorporated
mi
from
Sandusky, OH
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
North Coast Cancer Care, Incorporated
mi
from
Sandusky, OH
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Flower Hospital Cancer Center
mi
from
Sylvania, OH
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Flower Hospital Cancer Center
mi
from
Sylvania, OH
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Mercy Hospital of Tiffin
mi
from
Tiffin, OH
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Mercy Hospital of Tiffin
mi
from
Tiffin, OH
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Toledo Hospital
mi
from
Toledo, OH
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Toledo Hospital
mi
from
Toledo, OH
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
St. Vincent Mercy Medical Center
mi
from
Toledo, OH
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
St. Vincent Mercy Medical Center
mi
from
Toledo, OH
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Medical University of Ohio Cancer Center
mi
from
Toledo, OH
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Medical University of Ohio Cancer Center
mi
from
Toledo, OH
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
CCOP - Toledo Community Hospital
mi
from
Toledo, OH
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
CCOP - Toledo Community Hospital
mi
from
Toledo, OH
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Toledo Clinic, Incorporated - Main Clinic
mi
from
Toledo, OH
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Toledo Clinic, Incorporated - Main Clinic
mi
from
Toledo, OH
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
UVMC Cancer Care Center at Upper Valley Medical Center
mi
from
Troy, OH
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
UVMC Cancer Care Center at Upper Valley Medical Center
mi
from
Troy, OH
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Fulton County Health Center
mi
from
Wauseon, OH
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Fulton County Health Center
mi
from
Wauseon, OH
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Ruth G. McMillan Cancer Center at Greene Memorial Hospital
mi
from
Xenia, OH
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Ruth G. McMillan Cancer Center at Greene Memorial Hospital
mi
from
Xenia, OH
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
mi
from
Allentown, PA
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
mi
from
Allentown, PA
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Rapid City Regional Hospital
mi
from
Rapid City, SD
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Rapid City Regional Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated:  7/9/2015
Franciscan Skemp Healthcare - La Crosse Campus
mi
from
La Crosse, WI
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent
Status: Enrolling
Updated: 7/9/2015
Franciscan Skemp Healthcare - La Crosse Campus
mi
from
La Crosse, WI
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Mobile Infirmary Medical Center
mi
from
Mobile, AL
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Mobile Infirmary Medical Center
mi
from
Mobile, AL
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Aurora Presbyterian Hospital
mi
from
Aurora, CO
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Aurora Presbyterian Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Boulder Community Hospital
mi
from
Boulder, CO
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Boulder Community Hospital
mi
from
Boulder, CO
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Penrose Cancer Center at Penrose Hospital
mi
from
Colorado Springs, CO
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Penrose Cancer Center at Penrose Hospital
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Porter Adventist Hospital
mi
from
Denver, CO
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Porter Adventist Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Presbyterian - St. Luke's Medical Center
mi
from
Denver, CO
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Presbyterian - St. Luke's Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
St. Joseph Hospital
mi
from
Denver, CO
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
St. Joseph Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
Rose Medical Center
mi
from
Denver, CO
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
Rose Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  7/9/2015
CCOP - Colorado Cancer Research Program, Incorporated
mi
from
Denver, CO
Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 7/9/2015
CCOP - Colorado Cancer Research Program, Incorporated
mi
from
Denver, CO
Click here to add this to my saved trials